Germany · Delayed Price · Currency is EUR Autolus Therapeutics Statistics
Total Valuation
FRA:6A3A has a market cap or net worth of EUR 399.99 million. The enterprise value is 507.51 million.
| Market Cap | 399.99M |
| Enterprise Value | 507.51M |
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 6.12% |
| Owned by Institutions (%) | 18.66% |
| Float | 82.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.98 |
| PB Ratio | 4.24 |
| P/TBV Ratio | 4.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.03 |
| EV / Sales | 6.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.80, with a Debt / Equity ratio of 3.26.
| Current Ratio | 5.80 |
| Quick Ratio | 3.61 |
| Debt / Equity | 3.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.24 |
Financial Efficiency
Return on equity (ROE) is -120.42% and return on invested capital (ROIC) is -28.85%.
| Return on Equity (ROE) | -120.42% |
| Return on Assets (ROA) | -25.96% |
| Return on Invested Capital (ROIC) | -28.85% |
| Return on Capital Employed (ROCE) | -57.06% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 106,684 |
| Profits Per Employee | -332,828 |
| Employee Count | 754 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, FRA:6A3A has paid 529,053 in taxes.
| Income Tax | 529,053 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.26% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +5.26% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 1.31 |
| Relative Strength Index (RSI) | 63.74 |
| Average Volume (20 Days) | 912 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.62 |
Income Statement
In the last 12 months, FRA:6A3A had revenue of EUR 80.33 million and -250.62 million in losses. Loss per share was -0.94.
| Revenue | 80.33M |
| Gross Profit | -100.48M |
| Operating Income | -229.37M |
| Pretax Income | -250.09M |
| Net Income | -250.62M |
| EBITDA | -220.71M |
| EBIT | -229.37M |
| Loss Per Share | -0.94 |
Balance Sheet
The company has 198.99 million in cash and 307.58 million in debt, with a net cash position of -108.59 million.
| Cash & Cash Equivalents | 198.99M |
| Total Debt | 307.58M |
| Net Cash | -108.59M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 94.38M |
| Book Value Per Share | 0.35 |
| Working Capital | 264.73M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 8.60M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | -125.08% |
| Operating Margin | -285.53% |
| Pretax Margin | -311.32% |
| Profit Margin | n/a |
| EBITDA Margin | -274.74% |
| EBIT Margin | -285.53% |
| FCF Margin | n/a |
Dividends & Yields
FRA:6A3A does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
| Earnings Yield | -62.66% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |